Amyloidosis is rare, but not as rare as doctors once thought. The most common systemic form, light chain (AL) amyloidosis, affects roughly 10 to 15 people per million each year in the United States. That translates to about 4,000 to 5,000 new cases annually. But a second major type, ATTR amyloidosis, is turning out to be far more common than previously recognized, especially in older adults with heart failure.
How Common Is AL Amyloidosis?
AL amyloidosis, caused by abnormal antibody fragments that misfold and deposit in organs, is the type most people mean when they say “amyloidosis.” A study using U.S. insurance claims data found that incidence ranged from about 10 to 14 cases per million person-years between 2007 and 2015, with no statistically significant increase over that period. The number of people living with the diagnosis, however, rose sharply: from 15.5 cases per million in 2007 to 40.5 per million in 2015. By 2015, at least 12,000 adults in the U.S. were living with AL amyloidosis.
That growing prevalence likely reflects both better detection and longer survival with modern treatments, not a true surge in new cases. The median age at diagnosis has historically been in the mid-60s to mid-70s, depending on the population studied, and men are diagnosed about 1.2 to 1.7 times more often than women.
ATTR Amyloidosis Is More Common Than Once Believed
Transthyretin (ATTR) amyloidosis comes in two forms. Wild-type ATTR, sometimes called senile cardiac amyloidosis, results from the normal transthyretin protein misfolding with age. Hereditary ATTR (hATTR) is caused by a genetic mutation in the transthyretin gene. For decades, both were considered extremely rare. That picture has changed dramatically.
A multicenter study of heart failure patients over age 75 who had thickened heart walls found that 16.8% had ATTR cardiac amyloidosis. None of the diagnosed patients were under 75. This suggests that wild-type ATTR is a significant, underrecognized cause of heart failure in elderly patients, not a medical curiosity. Many of these people were previously labeled as having “heart failure with preserved ejection fraction” without anyone identifying the amyloid deposits causing it.
Hereditary ATTR also has a notable pocket of prevalence. A specific mutation in the transthyretin gene, known as V122I, is carried by 3 to 4% of African Americans. That means roughly 1.3 to 1.8 million Black Americans carry a gene variant that raises their risk of developing cardiac amyloidosis later in life. Not all carriers develop symptoms, but the mutation is far from obscure in this population.
AA Amyloidosis Is Declining
AA amyloidosis develops as a complication of chronic inflammatory diseases like rheumatoid arthritis and ankylosing spondylitis. The body produces a protein called serum amyloid A during prolonged inflammation, and over years, it can accumulate in the kidneys and other organs. This type was once a major concern for people with poorly controlled inflammatory conditions.
It appears to be fading. A systematic review found that among rheumatoid arthritis patients, AA amyloidosis prevalence ranged from 16.7% to 25.2% in studies published before 2010. After 2010, that number dropped to 0.7%. A similar pattern appeared in ankylosing spondylitis, with rates falling from 6 to 8.5% down to about 1%. The most likely explanation is that biologic therapies now suppress inflammation effectively enough to prevent the prolonged protein buildup that causes AA amyloidosis in the first place.
Localized Amyloidosis: Even Rarer
Sometimes amyloid deposits are confined to a single organ or tissue rather than spreading throughout the body. This localized form most commonly affects the respiratory system (26% of cases in one 14-year academic center review), followed by the gastrointestinal tract (17%), head and neck (17%), and genitourinary system (10%). Skin, soft tissue, and breast tissue account for most of the remainder. Localized amyloidosis generally carries a much better prognosis than systemic forms because the deposits don’t damage multiple organs simultaneously.
Why It Takes So Long to Diagnose
Part of the reason amyloidosis seems rarer than it is comes down to how difficult it is to catch. The symptoms, including fatigue, swelling, shortness of breath, and numbness, overlap with dozens of more common conditions. More than one-third of AL amyloidosis patients report symptoms for a year or longer before diagnosis. About half see four or more different physicians before anyone identifies the real problem. The time from the first hint of trouble to a confirmed diagnosis ranges from about 3 to 21 months.
Newer imaging tools are helping close this gap, particularly for ATTR amyloidosis. A nuclear bone scan using a radioactive tracer can identify ATTR cardiac amyloidosis with 94% sensitivity and up to 100% specificity in the strongest positive results, often eliminating the need for a heart biopsy. This scan has been a major reason more ATTR cases are being found: when doctors have a reliable, noninvasive test, they’re more willing to look.
Survival Varies Widely by Type and Stage
AL amyloidosis is the most serious form. A large Mayo Clinic study of over 1,300 patients found median overall survival of about 4 years from diagnosis, but that average obscures enormous variation. Patients diagnosed at the earliest stage can survive 8 years or more. Those diagnosed at the most advanced stage, typically with significant heart involvement, have a median survival as short as 5 to 6 months. For patients healthy enough to undergo stem cell transplant, outcomes are substantially better: those with early-stage disease can expect survival well beyond 8 years.
ATTR amyloidosis, particularly the wild-type form, tends to progress more slowly than AL amyloidosis. Many patients live years after diagnosis, especially now that targeted medications can stabilize the transthyretin protein and slow further deposits. Localized amyloidosis rarely affects life expectancy at all.
Putting the Numbers in Context
If you look only at new diagnoses of AL amyloidosis, it fits the classic definition of a rare disease: fewer than 200,000 people affected in the U.S. at any given time. But the total burden of all amyloidosis types combined is almost certainly much larger than official numbers suggest. Wild-type ATTR amyloidosis alone may account for a meaningful fraction of unexplained heart failure in people over 75. The “rarity” of amyloidosis is, in many cases, really a reflection of how often it goes unrecognized. As diagnostic tools improve and awareness grows, the gap between true prevalence and diagnosed prevalence will continue to narrow.